Cytokinetics: Early Myqorzo Traction Supports HCM Franchise Story, But Execution Risks Remain

What happened

Cytokinetics has launched Myqorzo in obstructive HCM and early uptake metrics—rapid market access, >30% new-to-brand share, and strong prescriber interest—signal commercial viability beyond Q1 2026 revenue. A Seeking Alpha article argues that label expansion into non-obstructive HCM via the MAPLE-HCM and ACACIA-HCM trials could double the addressable market and transform Myqorzo into a franchise. Our DeepValue report, however, cautioned that at a ~$7.7B valuation with a leveraged balance sheet and negative equity, the stock discounts aggressive assumptions: achieving a rapid launch share against Bristol Myers' entrenched Camzyos, which already treated >12,500 patients. While early adoption metrics are encouraging, they are still very early and do not yet confirm a durable share advantage; Camzyos' label simplification has narrowed Myqorzo's differentiation. The pivotal ACACIA-HCM data in Q2 2026 will be the true test of the multi-indication thesis, and until then, the risk-reward remains skewed to the downside given the crowded bullish positioning.

Implication

Investors should view the early Myqorzo metrics as promising but not yet transformative, given that the stock still prices in a high-ramp scenario against an incumbent (Camzyos) with proven commercial execution. The rapid market access and new-to-brand share are positive, but they must translate into sustained script growth and payer coverage to justify the current ~$7.7B market cap. The balance sheet remains pressured with negative equity and ~$100M quarterly cash burn, meaning any launch hiccup or ACACIA failure could force dilutive financing. The thesis delta is that the initial commercial data de-risks the obstructive HCM opportunity modestly but does not alter the core risk: the stock is pricing in a multi-indication win that hinges on ACACIA success. Until that readout, we maintain a cautious stance and recommend trimming on strength, with a re-assessment window after ACACIA results.

Thesis delta

The early Myqorzo launch metrics reduce—but do not eliminate—the risk of a failed commercial ramp in obstructive HCM, shifting the thesis slightly toward a 'show-me' stance rather than outright skepticism. However, the bear case (Camzyos retains share, ACACIA fails) remains viable, and the stock's high valuation still discounts a best-case scenario. Investors should now focus on whether Myqorzo can sustain momentum and, more importantly, whether ACACIA-HCM delivers a positive result in Q2 2026 to validate the franchise expansion.